Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.

March 21, 2025

Vol.51 No.11

By Claire Marie Porter and Jacquelyn Cobb

Clinical Roundup

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Immunovia completes second clinical validation of next-gen pancreatic cancer test

Immunovia announced results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Pitt study offers insights into ovarian cancer’s origins

Researchers at the University of Pittsburgh have identified a trigger of high-grade serous ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.

March 07, 2025

Vol.51 No.09

Drugs & Targets

FDA approves Tevimbra + chemo for advanced ESCC

FDA approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1).

March 07, 2025

Vol.51 No.09

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

YOU MAY BE INTERESTED IN

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Immunovia completes second clinical validation of next-gen pancreatic cancer test

Pitt study offers insights into ovarian cancer’s origins

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

FDA approves Tevimbra + chemo for advanced ESCC

Renew today!

Subscriber content

Never miss an issue!

Login